Scholar Rock Holding (SRRK) Non-Current Debt (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Non-Current Debt of $196.6 million for Q1 2026, up 295.28% year-over-year from $49.7 million in Q1 2025, and up 97.19% quarter-over-quarter from $99.7 million in Q4 2025.
Scholar Rock Holding (SRRK) Non-Current Debt (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Non-Current Debt history runs 10 years deep, the most recent figure standing at $196.6 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 295.28% year-over-year to $196.6 million; the TTM figure through Mar 2026 stood at $196.6 million (up 295.28% YoY), while the FY2025 annual figure was $99.7 million, up 98.84% from the prior year.
- Non-Current Debt for Q1 2026 stood at $196.6 million, up from $99.7 million in the prior quarter.
- The five-year high for Non-Current Debt was $196.6 million in Q1 2026, with the low at $38.8 million in Q2 2022.
- The 5-year median for Non-Current Debt is $49.8 million (2022), against an average of $62.9 million.
- The sharpest annual moves came in 2024 and 2026: Non-Current Debt decreased 10.51% in 2024, then soared 295.28% in 2026.
- Scholar Rock Holding's Non-Current Debt stood at $49.7 million in 2022, then decreased by 2.13% to $48.7 million in 2023, then rose by 3.0% to $50.1 million in 2024, then soared by 98.84% to $99.7 million in 2025, then surged by 97.19% to $196.6 million in 2026.
- Business Quant data shows SRRK's Non-Current Debt at $196.6 million in Q1 2026, $99.7 million in Q4 2025, and $100.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | 196.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 196.20 Mn |
| Mar 31, 2026 | 196.61 Mn |
| Dec 31, 2025 | 99.71 Mn |
| Sep 30, 2025 | 100.00 Mn |
| Jun 30, 2025 | 49.76 Mn |
| Mar 31, 2025 | 49.74 Mn |
| Dec 31, 2024 | 50.15 Mn |
| Sep 30, 2024 | 50.10 Mn |
| Jun 30, 2024 | 48.49 Mn |
| Mar 31, 2024 | 44.59 Mn |
| Dec 31, 2023 | 48.68 Mn |
| Sep 30, 2023 | 49.96 Mn |
| Jun 30, 2023 | 49.90 Mn |
| Mar 31, 2023 | 49.83 Mn |
| Dec 31, 2022 | 49.74 Mn |
| Sep 30, 2022 | 49.77 Mn |
| Jun 30, 2022 | 38.81 Mn |
| Mar 31, 2022 | 43.62 Mn |
| Dec 31, 2021 | 48.42 Mn |
| Sep 30, 2021 | 24.93 Mn |